SG11201911603SA - ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION - Google Patents

ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION

Info

Publication number
SG11201911603SA
SG11201911603SA SG11201911603SA SG11201911603SA SG11201911603SA SG 11201911603S A SG11201911603S A SG 11201911603SA SG 11201911603S A SG11201911603S A SG 11201911603SA SG 11201911603S A SG11201911603S A SG 11201911603SA SG 11201911603S A SG11201911603S A SG 11201911603SA
Authority
SG
Singapore
Prior art keywords
enhancing agents
raav vector
cell transfection
improved cell
vector production
Prior art date
Application number
SG11201911603SA
Other languages
English (en)
Inventor
Guang Qu
Lin Lu
Jesusa Josue-Almqvist
John Fraser Wright
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of SG11201911603SA publication Critical patent/SG11201911603SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201911603SA 2017-06-07 2018-06-06 ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION SG11201911603SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516432P 2017-06-07 2017-06-07
US201762531626P 2017-07-12 2017-07-12
PCT/US2018/036344 WO2018226887A1 (en) 2017-06-07 2018-06-06 ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION

Publications (1)

Publication Number Publication Date
SG11201911603SA true SG11201911603SA (en) 2020-01-30

Family

ID=64566378

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911603SA SG11201911603SA (en) 2017-06-07 2018-06-06 ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION

Country Status (15)

Country Link
US (1) US20200165632A1 (zh)
EP (1) EP3635108A4 (zh)
JP (2) JP2020524498A (zh)
KR (1) KR20200033840A (zh)
CN (1) CN110997912A (zh)
AU (1) AU2018281306A1 (zh)
BR (1) BR112019025792A2 (zh)
CA (1) CA3066358A1 (zh)
CL (1) CL2019003561A1 (zh)
CO (1) CO2019014704A2 (zh)
IL (1) IL271190A (zh)
PE (1) PE20200619A1 (zh)
PH (1) PH12019502774A1 (zh)
SG (1) SG11201911603SA (zh)
WO (1) WO2018226887A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
BR112018011193A2 (pt) * 2015-12-01 2018-11-21 Spark Therapeutics Inc métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico
CN112567027A (zh) * 2018-08-10 2021-03-26 再生生物股份有限公司 用于重组aav生产的可扩展方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP2022521755A (ja) * 2019-02-22 2022-04-12 ライフ テクノロジーズ コーポレーション アデノ随伴ウイルスの産生のための浮遊システム
AU2020338014A1 (en) * 2019-08-28 2022-03-03 University Of Florida Research Foundation, Incorporated Improved production of recombinant AAV using embryonated avian eggs
CN111363761A (zh) * 2020-03-17 2020-07-03 苏州吉恒基因科技有限公司 利用阳离子多聚体dna复合物促进aav介导的基因表达方法
WO2022043926A1 (en) * 2020-08-31 2022-03-03 Intas Pharmaceuticals Ltd. Process for preparation of recombinant adeno-associated virus particle
WO2022079082A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation
CN116406425A (zh) 2020-10-15 2023-07-07 豪夫迈·罗氏有限公司 用于va rna转录的核酸构建体
TW202309294A (zh) * 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
JPWO2023053899A1 (zh) 2021-10-01 2023-04-06
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101633520B1 (ko) * 2008-03-14 2016-06-24 트랜스진 에스.에이. Csf-1r에 대한 항체
US20110212526A1 (en) * 2008-03-18 2011-09-01 National Tsing Hua University Method for producing recombinant adeno-associated virus
JP5697123B2 (ja) * 2009-07-27 2015-04-08 国立大学法人 千葉大学 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
US20150147274A1 (en) * 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
CA3051089C (en) * 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
NZ711019A (en) * 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
KR101833602B1 (ko) * 2013-02-26 2018-02-28 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
BR112015023024B1 (pt) * 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
WO2015031686A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
JP6574431B2 (ja) * 2014-02-24 2019-09-11 タケダ ゲー・エム・ベー・ハーTakeda GmbH Uti融合タンパク質
CA2992096A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells

Also Published As

Publication number Publication date
PH12019502774A1 (en) 2020-09-28
PE20200619A1 (es) 2020-03-11
JP2020524498A (ja) 2020-08-20
BR112019025792A2 (pt) 2020-07-07
RU2019143489A (ru) 2021-07-12
JP2023113706A (ja) 2023-08-16
CN110997912A (zh) 2020-04-10
EP3635108A1 (en) 2020-04-15
IL271190A (en) 2020-01-30
CO2019014704A2 (es) 2020-04-24
KR20200033840A (ko) 2020-03-30
CL2019003561A1 (es) 2020-06-12
US20200165632A1 (en) 2020-05-28
CA3066358A1 (en) 2018-12-13
EP3635108A4 (en) 2021-03-31
RU2019143489A3 (zh) 2022-04-07
AU2018281306A1 (en) 2020-01-16
WO2018226887A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
IL271190A (en) Enhancers for enhanced cell transfection and/or raav vector production
IL251504A0 (en) car expression vector and t cells expressing car
IL247729B1 (en) Improved aav vectors produced in insect cells
IL262359A (en) In vitro bite-activated T cells
IL269334A (en) Improved compositions of t cells and methods
SG11202002045RA (en) Cell
GB201710126D0 (en) Vectors & Methods
GB201712597D0 (en) Improved bioreactors
HK1251543A1 (zh) 穩定電解質材料及含有該材料的溶液材料
GB201712733D0 (en) Methods & cells
GB201713078D0 (en) T Cell Modification
GB201707779D0 (en) Cell
IL271022A (en) Compositions and methods for providing cell replacement therapy
SG10202110989QA (en) Large scale pei-mediated plasmid transfection
GB2571415B (en) Improved tinting shampoos
GB201718697D0 (en) Cell
GB201714180D0 (en) Transduced cell cryoformulation
IL274178A (en) Add-with-carry vector instruction
IL273247A (en) New cell row and its uses
GB2566572B (en) Methods for adeno-associated viral vector production
GB201718294D0 (en) Vector construct
GB201707782D0 (en) Cell
GB201707780D0 (en) Cell
GB201707781D0 (en) Cell
GB201706123D0 (en) Cell